Dr. Al-Kali on FDA Approval of Enasidenib in AML

Aref Al-Kali, MD
Published: Tuesday, Aug 01, 2017



Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).
SELECTED
LANGUAGE


Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x